

Risk Factors of Pancreatic Cancer in Patients With Type 2 Diabetes Mellitus: The Hong Kong Diabetes Study

Raymond Ngai Chiu Chan,¹ Teddy Tai Loy Lee,¹ Oscar Hou In Chou,¹ Jenny So,¹ Cheuk To Chung,¹ Edward Christopher Dee,² Kenrick Ng,³ Pias Tang,¹ Leonardo Roever,⁴ Tong Liu,⁵ Wing Tak Wong,⁶ Gary Tse,^{5,7} and Sharen Lee¹

¹Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, China–UK Collaboration, Hong Kong, China

²Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York, USA

³Department of Medical Oncology, University College London Hospitals NHS Foundation Trust, London, UK

⁴Department of Clinical Research, Federal University of Uberlandia, Uberlandia, Brazil

⁵Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China

⁶School of Life Sciences, The Chinese University of Hong Kong, Hong Kong, China

⁷Kent and Medway Medical School, University of Kent and Canterbury Christ Church University, Canterbury, CT2 7NT, UK

Correspondence: Gary Tse, MD, PhD, Tianjin Key Laboratory of Ionic-Molecular Function of Cardiovascular Disease, Department of Cardiology, Tianjin Institute of Cardiology, Second Hospital of Tianjin Medical University, Tianjin 300211, China; Kent and Medway Medical School, Canterbury, Kent, CT2 7NT, UK. Email: gary.tse@kmmms.ac.uk; or Sharen Lee, MBChB, Diabetes Research Unit, Cardiovascular Analytics Group, Hong Kong, HKG, China–UK Collaboration. Email: sharen212@gmail.com.

Abstract

Context: Diabetes mellitus (DM) is associated with the development of pancreatic cancer (PaC), but few large-scale studies have examined its predictive risk factors.

Objective: The present study aims to examine the predictors for PaC in patients with type 2 diabetes mellitus (T2DM) in a territory-wide, retrospective cohort study.

Methods: This was a territory-wide, retrospective cohort study of patients with T2DM mellitus older than 40 years with no prior history of PaC. Baseline demographics, use of antidiabetic medications, comorbidities, and biochemical parameters were extracted. Cox regression was used to calculate hazard ratios (HR) with 95% CI. Subgroup analyses based on chronic kidney disease (CKD) stages were performed.

Results: This study consisted of 273 738 patients (age = 65.4 ± 12.7 years, male = 48.2%, follow-up duration = 3547 ± 1207 days, disease duration = 4.8 ± 2.3 years), of whom 1148 developed PaC. The number of antidiabetic medications prescribed (HR: 1.20; 95% CI, 1.01–1.42; *P* = .040), diabetic microvascular complications (HR: 1.91; 95% CI, 1.30–2.81; *P* < .001), chronic kidney disease (HR: 1.81; 95% CI, 1.25–2.64; *P* = .002), use of acarbose (HR: 2.24; 95% CI, 1.35–3.74; *P* = .002), and use of glucagon-like peptide-1 receptor agonist (HR: 4.00; 95% CI: 1.28–12.53, *P* = .017) were associated with PaC development on multivariable Cox regression adjusting for the duration of DM, mean glycated hemoglobin A_{1c}, and history of pancreatic diseases. Stage 3A CKD or below was associated with PaC but not stage 3B or beyond.

Conclusion: Diabetic microvascular complications, especially stage 1, 2, and 3A CKD, were associated with PaCs.

Key Words: diabetes, pancreatic cancer, chronic kidney disease, diabetic microvascular complications

Abbreviations: ALP, alkaline phosphatase; CDARS, Clinical Data Analysis and Reporting System; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; FBG, fasting blood glucose; GLP-1, glucagon-like peptide-1 receptor agonist; HbA_{1c}, glycated hemoglobin A_{1c}; HDL, high-density lipoprotein cholesterol; HF, heart failure; HR, hazard ratio; ICD-9, International Classification of Diseases Ninth Revision; LDL, low-density lipoprotein cholesterol; PaC, pancreatic cancer; T2DM, type 2 diabetes mellitus.

Diabetes mellitus (DM) is a global public health concern currently affecting around 463 million patients worldwide. Current estimates predict a further rise of 51% by 2045 [1]. DM has long been associated with a number of microvascular and macrovascular complications. In recent years, more attention has been drawn to the association between DM and various cancers [2–4]. Several meta-analyses were published establishing the relations between DM and many common malignancies including lung cancer, gastric cancer, colorectal cancer, hepatocellular carcinoma, breast cancer, as well as cancer mortality [5–10].

Pancreatic cancer (PaC), a relatively rare yet highly aggressive malignancy, is associated with a dismal prognosis and has a 5-year-survival rate of less than 5% [11]. It is currently the third leading cause of cancer-related death in the United States [12]. Despite advances in oncological treatments over previous decades, it remains a growing source of cancer death, potentially because of difficulty in diagnosis and delayed treatment. Identifying patients at risk of developing PaC and subsequent workups may hence be important to improve the prognosis.

Meanwhile, PaC has been associated with DM [13–15]. In a meta-analysis of 35 cohort studies in 2011, DM was identified

as a risk factor of PaC independent of sex, alcohol consumption, body mass index, and smoking [16]. In another meta-analysis conducted in 2015, Song et al [17] pooled data from 44 studies and further reported that a long DM duration was associated with an elevated risk of PaC of up to 64%. In addition, DM predicts not only incident PaC, but also PaC-related mortality. A large-scale cohort study of 1 089 586 individuals in the United States reported an adjusted risk ratio of up to 2.05 for PaC mortality in DM patients compared to those without DM [18].

However, although DM patients are at higher risks of developing PaC, risk stratification is imperfect as there is limited literature reporting the potential risk factors of PaC in DM patients thus far. Therefore, the present study aims to examine the predictors for PaC in patients with type 2 DM (T2DM) in a territory-wide, retrospective cohort study.

Materials and Methods

Study Design and Data Source

This study was approved by the Joint Chinese University of Hong Kong-New Territories East Cluster Clinical Research Ethics Committee. It was a population-based, territory-wide, retrospective cohort study with the data from the Clinical Data Analysis and Reporting System (CDARS), an electronic medical database that captures inpatient and outpatient data from all public hospitals and clinics in Hong Kong, China. CDARS facilitates the retrieval of clinical data from differential operation systems in health care institutes to provide integrated clinical data and represents approximately 80% of the population [19]. With the use of CDARS, local teams have conducted numerous epidemiological studies previously, including those on DM [19–23]. Confidentiality was ensured by anonymization of data from all subjects.

Participants and Data Collection

Patients with T2DM older than 40 years from January 1, 2009 to December 31, 2009, were identified. DM was defined by the International Classification of Disease, Ninth Revision (ICD-9) coding system and/or exposure to any antihyperglycemic agents. Diabetes disease duration was defined as the date difference between the earliest of 1) earliest record of T2DM-related ICD-9 codes; 2) earliest record of glycated hemoglobin A_{1c} (HbA_{1c}) greater than 6.5%; and 3) earliest record of fasting blood glucose (FBG) greater than 7 mmol/L and the baseline date. Baseline data were defined as data obtained closest to January 1, 2009. Individuals with a history of PaC before baseline were excluded. PaC was defined by the ICD-9 coding system. All participants were followed from baseline until the date of PaC, registered death, last follow-up, or August 16, 2020, whichever came first.

Demographic information including date of birth, age, sex, and date of registered death was captured. The following classes of antidiabetic medications were extracted: 1) biguanide; 2) sulfonylurea; 3) insulin; 4) thiazolidinedione; 5) alpha-glucosidase inhibitor; and 6) glucagon-like peptide-1 receptor agonist (GLPA). The use of these agents was defined as any exposure at or before baseline.

At baseline, laboratory data from complete blood count (lymphocyte count, neutrophil count, and hemoglobin level), liver function test (alanine transaminase, alkaline phosphatase [ALP], albumin, and total protein), renal function test

(creatinine, urea, and estimated glomerular filtration rate [eGFR]), lipid profile (high-density lipoprotein cholesterol (HDL), low-density lipoprotein cholesterol (LDL-), total cholesterol, triglycerides), and glycemic profile (FBG, HbA_{1c}) between January 1, 2008 to December 31, 2008, were obtained. In addition, mean HbA_{1c} and FBG from January 1, 2008 to December 31, 2008, were extracted. Baseline anemia was defined as hemoglobin count less than 13 g/dL among men, and less than 12 g/dL among women.

The following preexisting comorbidities were identified using ICD-9 codes (Supplementary Table 1) [24]: 1) diabetic retinopathy; 2) diabetic neuropathy; 3) peripheral vascular disease; 4) ischemic stroke; 5) sudden cardiac death; 6) atrial fibrillation; 7) heart failure (HF); 8) ischemic heart disease; 9) hypertension; 10) dementia; 11) cancer; 12) depression; 13) acute pancreatitis; 14) chronic pancreatitis; 15) pancreatic cyst. Chronic kidney disease (CKD) was defined by ICD-9 or an eGFR less than 90 mL/min/1.73 m². Stage < 2, 3A, 3B, 4, and 5 CKD were defined as eGFR greater than 60, 59 to 45, 44 to 30, 29 to 15, and less than 15 mL/min/1.73 m², respectively. Hyperlipidemia was defined by ICD-9, triglycerides greater than 1.7 mmol/L or LDL greater than 3.4 mmol/L. Diabetic microvascular complications were defined as CKD, diabetic retinopathy, or diabetic neuropathy. Diabetic macrovascular complications were defined as peripheral vascular disease, ischemic stroke, sudden cardiac death, atrial fibrillation, HF, or ischemic heart disease. Pancreatic disease was defined by ICD-9, acute pancreatitis, chronic pancreatitis, or benign pancreatic cyst.

Statistical Analysis

Data were analyzed using R Studio software (version 1.1.456). Continuous variables were expressed as mean ± SD while categorical variables were expressed as frequency (percentage). Qualitative and quantitative differences between participants who developed PaC and those who did not were analyzed using chi-square or Fisher exact tests for categorical data and *t* test, Mann-Whitney test, one-way analysis of variance, and Kruskal-Wallis test for continuous data, where appropriate. Unadjusted hazard ratios (HRs) were calculated using a univariable Cox regression model after censoring for death. It is presented with 95% CI. Variables with *P* less than .05 will be included in the multivariable analysis. Adjusted HRs were then calculated using multivariable Cox regression after censoring for death. We constructed 3 multivariable models to adjust for DM duration, DM duration and mean HbA_{1c}, as well as DM duration, mean HbA_{1c}, and pancreatic diseases respectively. Univariable and multivariable Cox regression was performed to assess the association of different stages of CKD and PaC. All statistical tests were 2-sided and statistical significance was taken as *P* less than .05.

Results

Baseline Characteristics

A total of 273 738 participants with DM were identified after excluding individuals with PaC before baseline (age = 65.4 ± 12.7 years, male = 48.2%, follow-up duration = 3547 ± 1207 days, DM duration = 4.8 ± 2.3 years). Their mean FBG

Table 1. Baseline characteristics of individuals who developed and did not develop pancreatic cancer

	No pancreatic cancer (n = 272 590)	Pancreatic cancer (n = 1148)	P
Basic demographics			
Male	131 397 (48.2)	562 (49.0)	.632
Age, y	65.4 (12.7)	69.1 (10.2)	< .001
Follow-up duration, d	3552.0 (1204.3)	2246 (1253)	< .001
DM duration, y	4.8 (2.3)	4.8 (2.2)	.872
HbA _{1c} , %	7.4 (1.5)	7.4 (1.3)	< .001
Mean HbA _{1c}	7.7 (1.2)	7.75 (1.16)	.163
Fasting blood glucose	7.8 (2.6)	7.59 (2.39)	.123
Mean fasting blood glucose	8.0 (1.9)	7.83 (1.68)	.005
No. of DM medications	1.4 (0.8)	1.5 (0.8)	.036
Death	89 993 (33.0)	1063 (93.6)	< .001
Microvascular complications	100 770 (37.0)	462 (40.2)	< .001
CKDs	100 366 (36.8)	460 (40.1)	< .001
Diabetic neuropathy	1159 (0.4)	3 (0.3)	.532
Diabetic retinopathy	3531 (1.3)	12 (1.0)	.537
Stage of CKD			< .001
< 2	56 808 (20.8)	283 (24.7)	
3A	21 249 (7.8)	109 (9.5)	
3B	13 131 (4.8)	48 (4.2)	
4	6025 (2.2)	15 (1.3)	
5	2885 (1.1)	4 (0.3)	
Macrovascular complication	41 796 (15.3)	159 (13.9)	.177
Peripheral vascular diseases	346 (0.1)	0 (0.0)	.429
Ischemic stroke	8950 (3.3)	27 (2.4)	.092
Sudden cardiac death	6391 (2.3)	26 (2.3)	.936
Atrial fibrillation	7744 (2.8)	23 (2.0)	.106
Heart failure	11 146 (4.1)	30 (2.6)	.014
Coronary heart disease	26 301 (9.6)	106 (9.2)	.671
Pancreatic diseases	510 (0.2)	18 (1.6)	< .001
Acute pancreatitis	275 (0.1)	3 (0.3)	.215
Chronic pancreatitis	110 (0.0)	5 (0.4)	< .001
Pancreatic cyst	119 (0.0)	2 (0.2)	.163
Other comorbidities			
Hypertension	63 941 (23.5)	259 (22.6)	.497
Hyperlipidemia	78 593 (28.8)	312 (27.2)	.143
Dementia	2833 (1.0)	8 (0.7)	.319
Other cancers	11 994 (4.4)	58 (5.1)	.316
Anemia	19 317 (7.1)	74 (6.4)	.432
Depression	4350 (1.6)	18 (1.6)	≥ .999
Liver function test			
ALP	79.8 (36.3)	83.8 (66.2)	.173
ALT	26.1 (24.4)	26.6 (27.8)	.708
Total protein	74.2 (7.0)	74.2 (6.0)	.873
Albumin	38.7 (5.4)	39.1 (4.9)	.064
Complete blood count			
Hemoglobin	12.4 (2.0)	12.6 (1.9)	.249

(continued)

Table 1. Continued

	No pancreatic cancer (n = 272 590)	Pancreatic cancer (n = 1148)	P
Lymphocytes	1.8 (1.1)	1.8 (0.8)	.436
Neutrophils	5.5 (2.8)	5.2 (2.5)	.221
Lipid profile			
HDL	1.2 (0.3)	1.2 (0.3)	.437
LDL	2.9 (0.9)	2.9 (0.8)	.443
Total cholesterol	4.8 (1.0)	4.7 (1.0)	.016
Triglycerides	1.7 (1.4)	1.6 (1.0)	.020
Renal function test			
Creatinine	103.6 (93.7)	92.2 (48.0)	< .001
Urea	6.9 (4.1)	6.4 (2.9)	< .001
eGFR	70.1 (24.8)	70.1 (20.8)	.978
DM medications			
Biguanide	184 999 (67.9)	814 (70.9)	.030
Sulfonylurea	172 693 (63.4)	742 (64.6)	.385
Insulin	29 540 (10.8)	120 (10.5)	.711
Pioglitazone	3680 (1.4)	18 (1.6)	.610
Alpha-glucosidase inhibitor	3265 (1.2)	23 (2.0)	.018
GLPA	336 (0.1)	4 (0.3)	.082

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated hemoglobin A_{1c}; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; GLPA, glucagon-like peptide-1 receptor agonist.

and HbA_{1c} were 8.00 ± 1.86 mmol/L and $7.75 \pm 2.6\%$, respectively. A total of 37.0% and 15.3% patients had microvascular and macrovascular complications at baseline; 67.9%, 63.4% and 10.8% patients were on metformin, sulfonylurea, and insulin, respectively. During follow-up, 33.3% of patients died. The demographic information of participants who developed and did not develop PaC during follow-up is summarized in [Table 1](#).

Of the 273 738 patients, 1148 (0.4%) developed PaC over a mean follow-up of 2246 ± 1253 days. Compared to patients who did not develop PaC, they were older, had higher frequencies of microvascular complications, CKD, HF, pancreatic diseases, and acute pancreatitis at baseline. They were on a higher number of antidiabetic medications, especially metformin and acarbose. Of the patients who developed incident PaC, 93.6% patients died during follow-up within the study period, reflecting the dismal prognosis of this cancer.

Pancreatic Diseases in Diabetic Mellitus Patients

Univariable Cox regression was used to identify the potential risk factors of PaC development. Pancreatic diseases were the strongest predictor of PaC with an unadjusted HR of 32.68 (95% CI, 18.05-59.18; $P < .001$). Of the 3 pancreatic diseases analyzed, chronic pancreatitis and pancreatic cyst were associated ([Table 2](#)). The association between pancreatic diseases and chronic pancreatitis remains statistically significant after adjustment by DM duration and mean HbA_{1c} ([Table 3](#)).

Table 2. Unadjusted hazard ratio for developing pancreatic cancer in diabetes mellitus patients

	Unadjusted HR	95% CI	P
DM duration	1.01	0.97-1.04	.779
HbA _{1c}	0.96	0.90-1.03	.244
Fasting blood glucose	0.97	0.94-1.01	.16
Mean HbA _{1c}	1.06	0.99-1.14	.115
Mean fasting blood glucose	0.933	0.89-0.98	.009
DM drug number	1.09	1.01-1.17	.022
Microvascular complication	1.72	1.37-2.15	< .001
Chronic kidney disease	1.70	1.36-2.12	< .001
Diabetic neuropathy	0.76	0.24-2.35	.628
Diabetic retinopathy	0.96	0.54-1.69	.874
Macrovascular complications	1.06	0.89-1.25	.526
Ischemic stroke	0.86	0.59-1.26	.431
Sudden cardiac death	1.16	0.79-1.71	.451
Atrial fibrillation	0.90	0.60-1.37	.632
Heart failure	0.91	0.63-1.30	.590
Coronary heart disease	1.09	0.89-1.33	.411
Pancreatic diseases	32.68	18.05-59.18	< .001
Acute pancreatitis	2.82	0.91-8.74	.074
Chronic pancreatitis	12.07	5.02-29.06	< .001
Pancreatic cyst	4.23	1.06-16.93	.042
Hypertension	1.09	0.95-1.25	.239
Hyperlipidemia	0.85	0.72-1.02	.076
Dementia	1.06	0.53-2.12	.879
Other cancers	1.42	1.09-1.85	.009
Anemia	1.28	1.01-1.61	.041
Depression	1.02	0.64-1.63	.93
ALP	1.00	1.00-1.00	< .001
ALT	1.00	1.00-1.00	.997
Total protein	0.99	0.97-1.01	.182
Albumin	0.99	0.97-1.02	.643
Hemoglobin	0.97	0.89-1.05	.414
Lymphocytes	0.98	0.79-1.20	.819
Neutrophils	0.99	0.93-1.05	.703
HDL	1.07	0.86-1.34	.600
LDL	0.95	0.85-1.06	.339
Total cholesterol	0.90	0.84-0.97	.004
Triglycerides	0.93	0.87-1.00	.041
Creatinine	1.00	1.00-1.00	.236
Urea	0.99	0.96-1.01	.354
eGFR	1.00	0.99-1.00	.008
Stage of CKD	1.07	1.00-1.16	.053
Metformin	1.08	0.95-1.23	.244
Sulfonylurea	1.08	0.96-1.22	.192
Insulin	1.09	0.90-1.31	.390
Pioglitazone	1.13	0.71-1.18	.615
Acarbose	1.76	1.16-2.65	.008
GLPA	2.67	1.00-7.12	.050

Abbreviations: ALP, alkaline phosphatase; ALT, alanine transaminase; CKD, chronic kidney disease; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HbA_{1c}, glycated hemoglobin A_{1c}; HDL, high-density lipoprotein cholesterol; HR, hazard ratio; LDL, low-density lipoprotein cholesterol; GLPA, glucagon-like peptide-1 receptor agonist.

Diabetic Complications and Comorbidities

Diabetic microvascular complications were associated with a higher risk of developing PaC during follow-up (HR: 1.72; 95% CI, 1.37-2.15; $P < .001$) (see Table 2). Among the 3 microvascular complications, only CKD was associated with PaC (HR: 1.70; 95% CI, 1.36-2.12; $P < .001$). The association for both diabetic microvascular complications and CKD remained statistically significant after adjustment for DM duration, mean HbA_{1c}, and pancreatic diseases (see Table 3). Given the association of CKD and PaC on multivariable regression, we further analyzed the association of the stage of CKD and eGFR with the development of PaC, but neither showed statistically significant associations (see Table 2). Patients were stratified according to CKD stage. Patients with less than stage 2 CKD were at greater risk of PaC after adjusting for DM duration, mean HbA_{1c}, and pancreatic diseases (HR: 1.91; 95% CI, 1.28-2.83; $P = .001$). Stage 3A CKD showed an even stronger association with a, HR of 2.16 (95% CI, 1.38-3.39; $P < .001$) (Table 4). No statistically significant association was found for any macrovascular complications (HR: 1.06; 95% CI, 0.89-1.25; $P = .526$) (see Table 2). A history of malignancy remained a statistically significant predictor for PaC (HR: 1.57; 95% CI, 1.00-2.48; $P = .050$) after adjusting for DM duration and mean HbA_{1c} (see Table 3).

Biochemical Parameters

Among all the parameters, only eGFR, ALP, total cholesterol, and triglycerides were associated with PaC in univariable analyses (see Table 2). The association of eGFR, total cholesterol, and triglycerides with PaC became insignificant after adjusting for DM duration (see Table 3). Only ALP produced a statistically significant association with PaC after adjustment for DM duration, mean HbA_{1c}, and pancreatic diseases, but the association was very weak (HR: 1.00; 95% CI, 1.00-1.01; $P = .040$).

Diabetic Control and Medications

Among the parameters of baseline diabetic control, only the number of DM medications produced a statistically significant association (HR: 1.09; 95% CI, 1.01-1.17; $P = .022$) (see Table 2). The association remained statistically significant after adjusting for DM duration, mean HbA_{1c}, and pancreatic diseases (see Table 3). GLPA (HR: 2.67; 95% CI, 1.00-7.12; $P = .050$) and alpha-glucosidase inhibitor (HR: 1.76; 95% CI, 1.16-2.65; $P = .008$) were associated with PaC both in univariable and multivariable analyses adjusting for DM duration, mean HbA_{1c}, and pancreatic diseases.

Discussion

This was a territory-wide, retrospective cohort study that aimed to identify the risk factors of developing PaC in DM patients, and is thus far one of the largest cohort studies for PaC specific to DM individuals that included demographic data, DM control, use of medications, and comorbidities at baseline for analysis. In our study, the following important findings were noted: 1) DM duration and diabetic control were not associated with risk of PaC; 2) no baseline biochemical parameters can predict PaC; 3) microvascular complications, in particular CKD, were strong predictors of PaC; and 4) the

Table 3. Adjusted hazard ratio for developing pancreatic cancer in diabetes mellitus patients

	Model 1	Model 2	Model 3
Mean fasting blood glucose	0.93 (0.87-1.00) <i>P</i> = .040	0.88 (0.81-0.96) <i>P</i> = .004	0.88 (0.81-0.96) <i>P</i> = .004
No. of DM medications	1.06 (0.96-1.17) <i>P</i> = .256	1.20 (1.01-1.42) <i>P</i> = .041	1.20 (1.01-1.42) <i>P</i> = .040
Microvascular complications	1.78 (1.32-2.40) <i>P</i> < .001	1.91 (1.30-2.81) <i>P</i> < .001	1.91 (1.30-2.81) <i>P</i> < .001
Chronic kidney disease	1.73 (1.29-2.31) <i>P</i> < .001	1.81 (1.25-2.64) <i>P</i> = .002	1.81 (1.25-2.64) <i>P</i> = .002
Pancreatic diseases	5.13 (2.29-11.45) <i>P</i> < .001	2.05 (0.50-8.25) <i>P</i> = .313	N/A
Chronic pancreatitis	12.44 (4.00-38.67) <i>P</i> < .001	11.45 (2.84-46.14) <i>P</i> < .001	N/A
Pancreatic cyst	6.71 (1.67-26.88) <i>P</i> = .003	0.00 (0.00-inf) <i>P</i> = .990	N/A
Other cancers	1.43 (1.02-2.01) <i>P</i> = .039	1.58 (1.00-2.48) <i>P</i> = .050	1.57 (1.00-2.48) <i>P</i> = .051
Anemia	1.21 (0.89-1.65) <i>P</i> = .224	1.01 (0.70-1.47) <i>P</i> = .952	1.01 (0.70-1.46) <i>P</i> = .976
ALP	1.00 (1.00-1.01) <i>P</i> < .001	1.00 (1.00-1.01) <i>P</i> = .036	1.00 (1.00-1.01) <i>P</i> = .040
Total cholesterol	0.93 (0.84-1.02) <i>P</i> = .111	0.97 (0.86-1.09) <i>P</i> = .584	0.97 (0.86-1.08) <i>P</i> = 0.583
Triglycerides	0.99 (0.92-1.07) <i>P</i> = .740	1.01 (0.93-1.09) <i>P</i> = .839	1.01 (0.93-1.09) <i>P</i> = .873
Alpha-glucosidase inhibitor	2.04 (1.24-3.35) <i>P</i> = .005	2.24 (1.34-3.73) <i>P</i> = .002	2.24 (1.35-3.74) <i>P</i> = .002
GLPA	4.54 (1.70-12.13) <i>P</i> = .003	3.99 (1.27-12.47) <i>P</i> = .018	4.00 (1.28-12.53) <i>P</i> = .017

Model 1: Adjusted for DM duration; model 2: adjusted for DM duration and mean HbA_{1c}; model 3 adjusted for DM duration, mean HbA_{1c}, and pancreatic diseases.

Abbreviations: ALP, alkaline phosphatase; DM, diabetes mellitus; GLPA, glucagon-like peptide-1 receptor agonist; HbA_{1c}, glycated hemoglobin A_{1c}; N/A, not available.

use of acarbose and GLP-based medications were associated statistically.

Diabetic Duration and Control

DM has been recognized as a risk factor of PaC by multiple studies and more recently several meta-analyses [13, 14, 16, 17, 25, 26]. Although there have been studies reporting the association between long DM duration and PaC, in our study we demonstrated that DM duration was not associated. While the meta-analysis in 2015 concluded that “long-term” DM was associated with an increased risk of PaC, findings from the present study echoed their findings in that a positive relation between DM duration and risk of PaC was not observed [17]. In their study, DM duration of 2 or more years was associated with a 64% increase in PaC risk, while the pooled risk ratio was only 1.50 for DM duration of 10 or more years. Similar data were also presented by Ben et al [16], who reported that patients with DM duration greater than 1 year had a relative risk greater than patients with DM duration greater than 5 years, showing that a longer DM duration did not result in a higher risk of PaC.

Meanwhile, for DM control, our data were similar to another large-scale population-based study consisting of 1 574 768 individuals in Sweden that showed that baseline HbA_{1c} at DM diagnosis was not associated with PaC [27]. We further evaluated the effect of mean HbA_{1c} to account

for variability in only one measurement and the result was similar. Although a sudden increase in HbA_{1c}, that is, new-onset DM, may be a symptom of PaC indicating that in case-control studies a higher HbA_{1c} was associated with PaC [28], this phenomenon was not observed by both population-based studies when PaC was relatively uncommon. Contrary to our findings, a meta-analysis showed that FBG was associated with PaC. However, their study included only 576 cases from 5 studies, and the heterogeneity was high between studies [29]. It is likely that glycemic control in patients with established DM was not associated with PaC.

Diabetic Complications and Pancreatic Cancer

In a nationwide, population-based study in Korea, prediabetic CKD including hypertensive nephropathy, diabetic nephropathy, and unspecified kidney failure was shown to be associated with PaC compared to the general population [30]. However, that study did not adjust for DM or other established risk factors of PaC. Whether CKD is an independent risk factor in the general or the DM population remains unclear. To the best of our knowledge, our present study is the first population-based cohort study to identify CKD as a risk factor of PaC in DM patients. This echoed the findings from a small-scale case-control study that included 433 PaC patients from a multiethnic cohort [31]. In both studies, CKD was significantly associated with PaC but not other

Table 4. Association of stages of chronic kidney disease and pancreatic cancer in diabetes mellitus patients

	Unadjusted HR	Model 1	Model 2	Model 3
< Stage 2	1.73 (1.37-2.18) <i>P</i> < .001	1.80 (1.33-2.45) <i>P</i> < .001	1.90 (1.28-2.82) <i>P</i> = .001	1.91 (1.28-2.83) <i>P</i> = .001
Stage 3A	1.91 (1.45-2.52) <i>P</i> < .001	1.98 (1.39-2.84) <i>P</i> < .001	2.16 (1.38-3.38) <i>P</i> < .001	2.16 (1.38-3.39) <i>P</i> < .001
Stage 3B	1.50 (1.06-2.13) <i>P</i> = .021	1.27 (0.78-2.04) <i>P</i> = .302	1.36 (0.77-2.41) <i>P</i> = .287	1.36 (0.77-2.41) <i>P</i> = .286
Stage 4	1.22 (0.71-2.12) <i>P</i> = .469	1.03 (0.49-2.18) <i>P</i> = .931	1.35 (0.62-2.95) <i>P</i> = .449	1.35 (0.62-2.93) <i>P</i> = .456
Stage 5	0.92 (0.34-2.51) <i>P</i> = .873	0.76 (0.18-3.14) <i>P</i> = .706	0.96 (0.23-4.02) <i>P</i> = .950	0.96 (0.23-4.04) <i>P</i> = .955

Model 1: Adjusted for DM duration; model 2: adjusted for DM duration and mean HbA_{1c}; model 3 adjusted for DM duration, mean HbA_{1c}, and pancreatic diseases.

Abbreviations: DM, diabetes mellitus; HbA_{1c}, glycated hemoglobin A_{1c}; HR, hazard ratio.

microvascular complications including diabetic retinopathy or neuropathy. As described in previous studies, DM and hyperglycemia contributed to the risk of PaC by attenuating antioxidant enzyme activity, and upregulating cellular levels of free radicals [32]. The role of advanced glycation products has also been implicated, given the fact that their receptors bind several important ligands in inflammation and carcinogenesis [33].

The present study showed that in addition to DM and hyperglycemia, CKD further elevated the risk of PaC. This may be a result of multiple factors including vitamin D deficiency, uremia, the proinflammatory state, and oxidative stress in CKD as proposed by previous studies [34–38]. Shortened leukocyte telomere length, which has been proposed to be a marker of oxidative stress and cellular aging, was also shown to be associated with both CKD and PaC [38, 39], highlighting their potential mechanistic relations. In addition to these shared pathways, CKD may also potentiate the effects of hyperglycemia on PaC development as exogenous or endogenous uremic toxins, angiotensin II, iron overload, and lipoperoxides create substantial amount of reactive oxygen species, which in turn upregulates advanced glycation products receptors expression via inhibition of glyceraldehyde-3-phosphate dehydrogenase and accumulation of upstream glycolytic intermediates [40, 41]. Such an association, together with the difficulty in diagnosing PaC in early stages, should alert physicians to the possibility of PaC whenever gastrointestinal symptoms arise in DM patients with CKD.

After identifying the association between CKD and PaC, we further analyzed the association of PaC with stage of CKD and eGFR respectively, but no statistically significant results were produced. Unadjusted and adjusted HRs were then calculated for each stage of CKD as compared to patients without CKD. Only stages before 3A were associated with PaC after adjustment but not stage 3B or above. The relatively fewer individuals having advanced stages of CKD and the shorter life expectancy may account for the loss of association beyond stage 3B and potentially explained the lack of association between eGFR and stages of CKD with PaC.

Antidiabetic Medication and Pancreatic Cancer

In the present study, we demonstrated that acarbose and GLPA were associated with PaC statistically. For GLPA, there have been historical concerns regarding the risk of PaC in

earlier observational studies [42]. Subsequently, several randomized controlled trials and meta-analyses were conducted, which confirmed the safety of GLPA [43]. The observed association between GLPA and PaC in previous studies was thought to be a result of confounding factors, which also potentially existed in the present study. Meanwhile, data on the risk of PaC in acarbose users were more scarce. Although a nationwide study in South Korea showed a small increase in the risk of PaC among alpha-glucosidase inhibitor users after adjustment [44], a meta-analysis of 4 studies reported no statistically significant associations [45]. Owing to the weight reduction effect, we postulate that GLPA and acarbose were more frequently prescribed in patients with higher body mass index, a traditional risk factor that we were not able to adjust for because of the retrospective nature of our study [46, 47]. Hence, the statistical association shown in the present study should be interpreted cautiously and further investigation is warranted.

Strengths and Limitations

With the use of data from CDARS, which represented approximately 80% of the local population, the present study had an adequate sample size and follow-up duration to detect relatively rare outcomes, such as PaC. It was also sufficiently powered to identify the association between PaC and different characteristics of the participants, including the different stages of CKD, which may not be possible for smaller cohorts. Nonetheless, there are still several limitations in our study. First, although CDARS has been recognized as a reliable source of integrated clinical data and has been used to produce numerous quality studies, there was unavoidably a risk of undercoding and coding errors. To partially compensate for the problems in coding, we captured several biochemical parameters, for example, FBG and HbA_{1c}, baseline creatinine and eGFR, triglycerides, and LDL, as well as hemoglobin, to define DM and its comorbidities like CKD, hyperlipidemia, and anemia. Second, data on DM duration and PaC were based on the date of the initial diagnosis in CDARS, which may or may not correspond to the actual date of diagnosis, especially if patients were diagnosed before January 1, 2009. Third, the relatively large number of individuals potentially resulted in high statistical significance but low HR in certain predictive parameters. The clinical significance may hence be limited. Fourthly, c-peptide was not measured in all individuals. Participants with DM secondary to pancreatic diseases

may be misclassified as T2DM. However, the overall number of patients with pancreatic diseases was very small and was unlikely to have major impacts on subsequent analyses. Finally, data on certain traditional risk factors of PaC, for example, family history, smoking, alcohol consumption, and obesity [48], were not available because of limitations of our database.

Conclusion

Early-stage CKD, a microvascular complication, significantly predicted PaC after adjusting for DM duration, mean HbA_{1c}, and pancreatic diseases, but not macrovascular complications. Further studies are required to establish the relations of these potential risk factors, and risk stratification of DM patients based on a combination of patient demographic, comorbidities, and use of medications is crucial.

Financial Support

The authors received no financial support for the research, authorship, and/or publication of this article.

Author Contributions

R.N.C.C.: study conception, data processing, data interpretation, statistical analysis, manuscript drafting, and critical revision of the manuscript; T.T.L.L. and O.H.I.C.: data acquisition, data processing, data interpretation, manuscript drafting, and critical revision of the manuscript; J.S., C.T.C., E.C.D., K.N., P.T., L.R., T.L., and W.T.W.: study planning, data interpretation, and critical revision of the manuscript; G.T. and S.L.: study conception, data processing, data interpretation, manuscript drafting, critical revision of the manuscript, and study supervision.

Disclosures

The authors have nothing to disclose.

Data Availability

Restrictions apply to the availability of some or all data generated or analyzed during this study to preserve patient confidentiality or because they were used under license. The corresponding author will on request detail the restrictions and any conditions under which access to some data may be provided.

References

- Saeedi P, Petersohn I, Salpea P, *et al*; IDF Diabetes Atlas Committee. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. *Diabetes Res Clin Pract.* 2019;157:107843.
- Chodick G, Heymann AD, Rosenmann L, *et al*. Diabetes and risk of incident cancer: a large population-based cohort study in Israel. *Cancer Causes Control.* 2010;21(6):879-887.
- Hemminki K, Li X, Sundquist J, Sundquist K. Risk of cancer following hospitalization for type 2 diabetes. *Oncologist.* 2010;15(6):548-555.
- Inoue M, Iwasaki M, Otani T, Sasazuki S, Noda M, Tsugane S. Diabetes mellitus and the risk of cancer: results from a large-scale population-based cohort study in Japan. *Arch Intern Med.* 2006;166(17):1871-1877.
- De Bruijn KM, Arends LR, Hansen BE, Leeflang S, Ruiter R, van Eijck CH. Systematic review and meta-analysis of the association between diabetes mellitus and incidence and mortality in breast and colorectal cancer. *Br J Surg.* 2013;100(11):1421-1429.
- Larsson SC, Orsini N, Wolk A. Diabetes mellitus and risk of colorectal cancer: a meta-analysis. *J Natl Cancer Inst.* 2005;97(22):1679-1687.
- Lee JY, Jeon I, Lee JM, Yoon JM, Park SM. Diabetes mellitus as an independent risk factor for lung cancer: a meta-analysis of observational studies. *Eur J Cancer.* 2013;49(10):2411-2423.
- Shimoyama S. Diabetes mellitus carries a risk of gastric cancer: a meta-analysis. *World J Gastroenterol.* 2013;19(40):6902-6910.
- Wang C, Wang X, Gong G, *et al*. Increased risk of hepatocellular carcinoma in patients with diabetes mellitus: a systematic review and meta-analysis of cohort studies. *Int J Cancer.* 2012;130(7):1639-1648.
- Coughlin SS, Calle EE, Teras LR, Petrelli J, Thun MJ. Diabetes mellitus as a predictor of cancer mortality in a large cohort of US adults. *Am J Epidemiol.* 2004;159(12):1160-1167.
- Zhang L, Sanagapalli S, Stoita A. Challenges in diagnosis of pancreatic cancer. *World J Gastroenterol.* 2018;24(19):2047-2060.
- Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. *CA Cancer J Clin.* 2022;72(1):7-33.
- Jee SH, Ohrr H, Sull JW, Yun JE, Ji M, Samet JM. Fasting serum glucose level and cancer risk in Korean men and women. *JAMA.* 2005;293(2):194-202.
- Larsson SC, Permert J, Håkansson N, Näslund I, Bergkvist L, Wolk A. Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. *Br J Cancer.* 2005;93(11):1310-1315.
- Jamal MM, Yoon EJ, Vega KJ, Hashemzadeh M, Chang KJ. Diabetes mellitus as a risk factor for gastrointestinal cancer among American veterans. *World J Gastroenterol.* 2009;15(42):5274-5278.
- Ben Q, Xu M, Ning X, *et al*. Diabetes mellitus and risk of pancreatic cancer: a meta-analysis of cohort studies. *Eur J Cancer.* 2011;47(13):1928-1937.
- Song S, Wang B, Zhang X, *et al*. Long-term diabetes mellitus is associated with an increased risk of pancreatic cancer: a meta-analysis. *PLoS One.* 2015;10(7):e0134321.
- Calle EE, Murphy TK, Rodriguez C, Thun MJ, Heath CW Jr. Diabetes mellitus and pancreatic cancer mortality in a prospective cohort of United States adults. *Cancer Causes Control.* 1998;9(4):403-410.
- Yip TC, Wong GL, Wong VW, *et al*. Reassessing the accuracy of PAGE-B-related scores to predict hepatocellular carcinoma development in patients with chronic hepatitis B. *J Hepatol.* 2020;72(5):847-854.
- Lee S, Zhou J, Leung KSK, *et al*. Development of a predictive risk model for all-cause mortality in patients with diabetes in Hong Kong. *BMJ Open Diabetes Res Care.* 2021;9(1):e001950.
- Lee S, Zhou J, Wong WT, *et al*. Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning. *BMC Endocr Disord.* 2021;21(1):94.
- Zhou J, Zhang G, Chang C, *et al*. Metformin versus sulphonylureas for new onset atrial fibrillation and stroke in type 2 diabetes mellitus: a population-based study. *Acta Diabetol.* 2022;59(5):697-709.
- Zhou J, Lee S, Wang X, *et al*. Development of a multivariable prediction model for severe COVID-19 disease: a population-based study from Hong Kong. *NPJ Digit Med.* 2021;4(1):66.
- Chan RNC, Lee TTL, Chou OHI, *et al*. Supplementary materials for "Risk factors of pancreatic cancer in patients with type 2 diabetes mellitus: The Hong Kong Diabetes Study." 2022. September 2, 2022; <https://doi.org/10.5281/zenodo.7042311>.
- Luo J, Iwasaki M, Inoue M, *et al*; JPHC Study Group. Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-

- based cohort study in Japan—the JPHC study. *Cancer Causes Control*. 2007;18(6):603-612.
26. Tan J, You Y, Guo F, Xu J, Dai H, Bie P. Association of elevated risk of pancreatic cancer in diabetic patients: a systematic review and meta-analysis. *Oncol Lett*. 2017;13(3):1247-1255.
 27. Lu Y, García Rodríguez LA, Malgerud L, *et al*. New-onset type 2 diabetes, elevated HbA1c, anti-diabetic medications, and risk of pancreatic cancer. *Br J Cancer*. 2015;113(11):1607-1614.
 28. Sadr-Azodi O, Gudbjörnsdóttir S, Ljung R. Pattern of increasing HbA1c levels in patients with diabetes mellitus before clinical detection of pancreatic cancer—a population-based nationwide case-control study. *Acta Oncol*. 2015;54(7):986-992.
 29. Pang Y, Kartsonaki C, Guo Y, *et al*. Diabetes, plasma glucose and incidence of pancreatic cancer: a prospective study of 0.5 million Chinese adults and a meta-analysis of 22 cohort studies. *Int J Cancer*. 2017;140(8):1781-1788.
 30. Oh HJ, Lee HA, Moon CM, Ryu DR. Incidence risk of various types of digestive cancers in patients with pre-dialytic chronic kidney disease: a nationwide population-based cohort study. *PLoS One*. 2018;13(11):e0207756.
 31. Farias AJ, Wu AH, Porcel J, *et al*. Diabetes-related complications and pancreatic cancer incidence in the multiethnic cohort. *JNCI Cancer Spectr*. 2020;4(5):pkaa035.
 32. Pizzato M, Turati F, Rosato V, La Vecchia C. Exploring the link between diabetes and pancreatic cancer. *Expert Rev Anticancer Ther*. 2019;19(8):681-687.
 33. Andersen DK, Korc M, Petersen GM, *et al*. Diabetes, pancreatogenic diabetes, and pancreatic cancer. *Diabetes*. 2017;66(5):1103-1110.
 34. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. *Am J Nephrol*. 2004;24(5):503-510.
 35. Wong G, Hayen A, Chapman JR, *et al*. Association of CKD and cancer risk in older people. *J Am Soc Nephrol*. 2009;20(6):1341-1350.
 36. Keller CR, Odden MC, Fried LF, *et al*. Kidney function and markers of inflammation in elderly persons without chronic kidney disease: the Health, Aging, and Body Composition Study. *Kidney Int*. 2007;71(3):239-244.
 37. Tonelli M, Sacks F, Pfeffer M, Jhargri GS, Curhan G; Cholesterol and Recurrent Events (CARE) Trial Investigators. Biomarkers of inflammation and progression of chronic kidney disease. *Kidney Int*. 2005;68(1):237-245.
 38. Gurung RL, Dorajoo R MY, Wang L, *et al*. Association of leukocyte telomere length with chronic kidney disease in East Asians with type 2 diabetes: a Mendelian randomization study. *Clin Kidney J*. 2021;14(11):2371-2376.
 39. Antwi SO, Petersen GM. Leukocyte telomere length and pancreatic cancer risk: updated epidemiologic review. *Pancreas*. 2018;47(3):265-271.
 40. Thomas MC, Brownlee M, Susztak K, *et al*. Diabetic kidney disease. *Nat Rev Dis Primers*. 2015;1:15018.
 41. Vaziri ND. Oxidative stress in uremia: nature, mechanisms, and potential consequences. *Semin Nephrol*. 2004;24(5):469-473.
 42. Elashoff M, Matveyenko AV, Gier B, Elashoff R, Butler PC. Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies. *Gastroenterology*. 2011;141(1):150-156.
 43. Cao C, Yang S, Zhou Z. GLP-1 receptor agonists and risk of cancer in type 2 diabetes: an updated meta-analysis of randomized controlled trials. *Endocrine*. 2019;66(2):157-165.
 44. Lee DY, Yu JH, Park S, *et al*. The influence of diabetes and antidiabetic medications on the risk of pancreatic cancer: a nationwide population-based study in Korea. *Sci Rep*. 2018;8(1):9719.
 45. Zhao Y, Wang Y, Lou H, Shan L. Alpha-glucosidase inhibitors and risk of cancer in patients with diabetes mellitus: a systematic review and meta-analysis. *Oncotarget*. 2017;8(46):81027-81039.
 46. Shah M, Vella A. Effects of GLP-1 on appetite and weight. *Rev Endocr Metab Disord*. 2014;15(3):181-187.
 47. Zhang F, Xu S, Tang L, Pan X, Tong N. Acarbose with comparable glucose-lowering but superior weight-loss efficacy to dipeptidyl peptidase-4 inhibitors: a systematic review and network meta-analysis of randomized controlled trials. *Front Endocrinol (Lausanne)*. 2020;11:288.
 48. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. *Nat Rev Gastroenterol Hepatol*. 2009;6(12):699-708.